Mechanistically, BET inhibitors sensitize melanoma cells to sunitinib by inhibiting the BRD4/GDF15 axis and the BRD4/IL6/STAT3/GDF15 axis (Fig. 7g). This evidence concerns the gene GDF15 and melanoma.